Biodistribution of Therapeutic Radioisotope Lu-177 Conjugated to MNPR-101 in Pancreatic Cancer (MIA PaCa-2) Tumor Xenograft
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
March 05, 2024 07:00 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., March 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
MNPR Triangle 2.JPG
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
February 27, 2024 07:00 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
Figure 1
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
February 22, 2024 07:00 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
MNPR Triangle 2.JPG
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
February 20, 2024 08:00 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
December 26, 2023 07:13 ET | Rayzebio, Inc.
Transaction Brings RayzeBio’s Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb’s Leading Oncology...
MNPR Triangle 2.JPG
Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments
November 09, 2023 07:00 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative...
MNPR Triangle 2.JPG
Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments
August 10, 2023 07:00 ET | Monopar Therapeutics Inc.
Camsirubicin Phase 1b Trial Currently at 5th Dose­-Level (650 mg/m2), Generating Encouraging ResultsMNPR-101 Radiopharma Program Advancing Toward First-in-Human Studies WILMETTE, Ill., Aug. 10, 2023...
MNPR Triangle 2.JPG
Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore
July 11, 2023 07:00 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., July 11, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, today...
MNPR Triangle 2.JPG
Monopar to Participate in the Radiopharma Forum by the Lake 2023
June 21, 2023 07:00 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., June 21, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
MNPR Triangle 2.JPG
Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments
May 11, 2023 07:00 ET | Monopar Therapeutics Inc.
Camsirubicin Phase 1b Dose­Escalation Trial Enrolling 5th Dose­Level Cohort (650 mg/m2)MNPR-101 RIT Shows Promising Imaging and Therapeutic Preclinical Study ResultsWILMETTE, Ill., May 11, 2023 (GLOBE...